

ASSIGNMENT

This Assignment Agreement is entered into by and between **Novartis Institute for Functional Genomics, Inc. dba Genomics Institute of the Novartis Research Foundation (GNF)**, 10675 John Jay Hopkins Drive, San Diego, CA 92121, a company organized under the laws of Delaware, and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

WHEREAS, Novartis Institute for Functional Genomics, Inc., hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of John Venable, by virtue of the assignment dated 6/20/2018 for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **Novartis Institute for Functional Genomics, Inc.** does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **June 22, 2017** and accorded U.S. Provisional Patent Application No.: **62/523,481**;

and filed in the United States Patent and Trademark Office on **February 28, 2018** and accorded Application Number **62/636,510**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____;¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

¹ Novartis Institute for Functional Genomics, Inc. appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by Novartis Institute for Functional Genomics, Inc. if this sale, assignment and transfer had not been made.

Novartis Institute for Functional Genomics, Inc. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Novartis Institute for Functional Genomics, Inc. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation

Executed this 20 day of June, 2018.

BY Julie McCarthy
Name: Julie McCarthy
Title: Authorized Signatory

Witnessed by:

J. Kallianay
Name: J.T. Kallianay
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Susan Semmes
Name: SUSAN SEMMES
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

NOVARTIS AG

Executed this 20th day of June, 2018.


BY 
Name: Emily T. Wu
Title: Authorized Signatory

Witnessed by:



Name: Jill Kalliamayi
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121



Name: SUSAN SEMMES
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Executed this 20th day of June, 2018.

BY 
Name: Kun Wang
Title: Authorized Signatory

Witnessed by:


Name: Jill Kalliamayi
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121


Name: SUSAN SEMMES
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

ASSIGNMENT

WHEREAS, I, Ansgar Brock, a citizen of Germany, having a mailing address of Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, CA 92121; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/523,481** filed **June 22, 2017**;

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, Novartis Institute for Functional Genomics, Inc. dba Genomics Institute of the Novartis Research Foundation (GNF), hereinafter referred to as the "ASSIGNEE", of 10675 John Jay Hopkins Drive, San Diego, CA 92121, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal

¹ I appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

10-10-2017
Date

Ansgar Brock
Ansgar Brock

Witnessed by:

J. Kalliomaa
Name: Jill Kalliomaa
Address: 10675 John Jay Hopkins Drive
San Diego, CA 92121

Susan Senneker
Name: Susan Senneker
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation

Executed this 13 day of October, 2017.

BY Julie McCarthy
Name: Julie McCarthy
Title: Authorized Signatory

Witnessed by:

J. Kallamada
Name: J. Kallamada
Address: 10675 John Jay Hopkins Drive
San Diego, CA 92121

Susan Sedovitch
Name: SUSAN SEDOVITCH
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

ASSIGNMENT

WHEREAS, We, **Scott Chappel**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Andrew Lake**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Alison Paterson**, a citizen of South Africa, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Rachel W. O'Connor**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Michael Warren**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; and **Pamela Holland**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/523,481** filed **June 22, 2017**;

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, **Surface Oncology, Inc.**, hereinafter referred to as the "ASSIGNEE", of 50 Hampshire Street, Cambridge, MA 02139, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

6/29/17
Date

Scott Chappel
Scott Chappel

Witnessed by:

Caroline Arnet
Name: Caroline Arnet
Address: 62 Wintergreen Dr
North Andover, MA
01845

Sandra Fay-Richard
Name: Sandra Fay-Richard
Address: 95 Baystate Rd
Belmont MA 02478

28 - Jun - 2017 
Date Andrew Lake

Witnessed by:

Maryann D. Vigliotta
Name:
Address:
Maryann D. Vigliotta
18 Hampden Av.
Burlington, MA
01803

Sandra Fay-Richard
Name: Sandra Fay-Richard
Address: 95 Baystate Rd
Belmont MA 02478

6/28/2017
Date



Alison Paterson

Witnessed by:

Maryann D. Vigliotta
Name:
Address:
Maryann D. Vigliotta
18 Hampden Ave.
Burlington, MA
01803

Sandra Fay-Richard
Name: Sandra Fay-Richard
Address: 95 Baystate Rd
Belmont MA 02478


6/28/2017
Date


Rachel W. O'Connor

Witnessed by:


Name:
Address:

Maryann D. Vigliotta
18 Hampden Ave.
Burlington, MA
01803


Name: Sandra Fay-Richard
Address: 95 Baystate Rd
Belmont MA 02478

6/28/17

Date

Michael Warren

Michael Warren

Witnessed by:

Maryann D. Vigliotta

Name:

Address:

Maryann D. Vigliotta
18 Hampden Ave.
Burlington, MA
01803

Sandra Fay

Name: Sandra Fay-Richard

Address:

95 Baystate Rd
Belmont MA 02478

July 10, 2017

Date

Pamela M. Holland

Pamela Holland

Witnessed by:

J. J. the

Name:

Address: 10 Hastings ST
Wellesley MA 02481


Sandra Fay-Richard

Name: Sandra Fay-Richard

Address: 95 Baystate Rd
Belmont MA 02478

Surface Oncology, Inc.

Executed this 10th day of July, 2017.

BY  L.S.


Name: Nicholas Buffinger
Title: Authorized Signatory

Witnessed by:


Name: Robert Ross

Address:

9 Somerset Rd
Brookline MA
02445


Name: Sandra Pay-Richard

Address:

95 Baystate Rd
Belmont MA 02478

ASSIGNMENT

WHEREAS, We, **Viviana Cremasco**, a citizen of the United States of America, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; **Glenn Dranoff**, a citizen of the United States of America, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; and **Catherine Anne Sabatos-Peyton**, a citizen of the United States of America, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/523,481** filed **June 22, 2017**;

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, **Novartis Institutes for BioMedical Research, Inc.**, hereinafter referred to as the "ASSIGNEE", of 250 Massachusetts Avenue, Cambridge, MA 02139, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.


10/6/17
Date

Viviana Gelluso
Viviana Cremasco

Witnessed by:

Susan M. Dillon
Name:
Address: Susan M. Dillon
700 Main Street
Cambridge, MA 02139 US

Kathleen M. Drury
Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139

February 2, 2018 
Date Glenn Dranoff

Witnessed by:

Kendra Mar
Name: Kendra Mar
Address: 250 Mass Ave
Cambridge, MA 02139

Susan M Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

6th October 2017
Date

Catherine Anne Sabatos-Peyton
Catherine Anne Sabatos-Peyton


Witnessed by:

Susan M Dillon
Name:
Address: Susan M. Dillon
700 Main Street
Cambridge, MA 02139 US


Kathleen M. Drury
Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139


Novartis Institutes for BioMedical Research Inc.

Executed this 9 day of February, 2018.

BY  L.S.
Name: Stephanie R. O'Neil
Title: Authorized Signatory

Witnessed by:


Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139


Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Ave., Cambridge, MA 02139, USA, a company organized under the laws of Delaware, and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

WHEREAS, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of Viviana Cremasco, Glenn Dranoff, and Catherine Anne Sabatos-Peyton, by virtue of the assignments dated 10/6/2017, 2/2/2018, and 10/6/2017 for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **June 22, 2017** and accorded U.S. Provisional Patent Application No.: **62/523,481**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____; and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____.¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and

¹ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. if this sale, assignment and transfer had not been made.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.


Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

Executed this 9 day of February, 20 18

BY  L.S.

Name: Stephanie K. Ellis
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name:
Address: Susan M. Dillon
700 Main Street
Cambridge, MA 02139 US

NOVARTIS AG

Executed this 1st day of February, 2018.

BY Safiya Watson L.S.
Name: Safiya Watson
Title: Authorized Signatory

BY Scott W. Loftis-Kend L.S.
Name: Scott W. Loftis-Kend
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name:
Address: **Kathleen M. Drury
700 Main Street
Cambridge, MA 02139**

Susan M. Dillon
Name:
Address: **Susan M. Dillon
700 Main Street
Cambridge, MA 02139 US**

ASSIGNMENT

This Assignment Agreement is entered into by and between **Novartis Institute for Functional Genomics, Inc. dba Genomics Institute of the Novartis Research Foundation (GNF)**, 10675 John Jay Hopkins Drive, San Diego, CA 92121, a company organized under the laws of Delaware, and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

WHEREAS, Novartis Institute for Functional Genomics, Inc., hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of Ansgar Brock, by virtue of the assignment dated 10/10/2017, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **Novartis Institute for Functional Genomics, Inc.** does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **June 22, 2017** and accorded U.S. Provisional Patent Application No.: **62/523,481**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____; and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____;¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and

¹ Novartis Institute for Functional Genomics, Inc. appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by Novartis Institute for Functional Genomics, Inc. if this sale, assignment and transfer had not been made.

Novartis Institute for Functional Genomics, Inc. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Novartis Institute for Functional Genomics, Inc. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and

discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation

Executed this 13 day of October, 2017

BY Julie McCarthy
Name: Julie McCarthy
Title: Authorized Signatory


Witnessed by:

J. Kalliomäki
Name: Jiri Kalliomäki
Address: 10675 John Jay Hopkins Drive
San Diego, CA 92121


Susan Semmel
Name: SUSAN SEMMEL
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121


NOVARTIS AG

Executed this 13th day of October, 2017.

BY 
Name: EMILY WU
Title: Authorized Signatory


Witnessed by:


Name: J. Kalliomäki
Address: 10675 John Jay Hopkins Drive
San Diego, CA 92121


Name: SUSAN SESNO
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

BY 
Name: KUN WANG
Title: Authorized Signatory

Witnessed by:


Name: J. Kalliomäki
Address: 10675 John Jay Hopkins Drive
San Diego, CA 92121


Name: SUSAN SESNO
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

ASSIGNMENT

This Assignment Agreement is entered into by and between **Adimab, LLC**, 7 Lucent Drive, Lebanon, NH 03766, a company organized under the laws of Delaware, and **Surface Oncology, Inc.**, a company organized under the laws of Delaware whose address is 50 Hampshire Street, Cambridge, MA 02139.

WHEREAS, **Adimab, LLC**, hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of Bianka Prinz and Jerry M. Thomas, by virtue of the assignment dated 3/28/18 and 3/22/18, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **Adimab, LLC** does hereby sell, assign and transfer to **Surface Oncology, Inc.** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **June 22, 2017** and accorded U.S. Provisional Patent Application No.: **62/523,481**;

and filed U.S. Provisional Patent Application Serial No.: **62/636,510** filed **February 28, 2018**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____; and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____;¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

¹ Adimab, LLC appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by Adimab, LLC if this sale, assignment and transfer had not been made.

Adimab, LLC hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Adimab, LLC hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.


Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Delaware.


This Assignment is effective as from the earliest priority date as stated above.


Adimab, LLC

Executed this 6th day of April, 2018.

BY  L.S.
Name: ERIC KRAWLAND
Title: Authorized Signatory

Witnessed by:


Name: Philip Chase
Address: 58 Rochester Rd., Newton MA


Name: Ross P Connor
Address: 18 Rolling Ridge Rd, Lebanon NH 05766

Surface Oncology, Inc.

Executed this 9th day of April, 2018.

BY Sandra Fay R L.S.
Name: Sandra Fay-Richard
Title: Authorized Signatory

Witnessed by:

Jamie Strad
Name: Jamie Strad
Address: 184 Cedar Ave
Arlington, MA 02476

Eileen M Woodbury
Name: Eileen M. Woodbury
Address: 6 Garden Lane
Apt 3.
Waltham, MA 02452

ASSIGNMENT

WHEREAS, I, John Delmas Venable III, a citizen of the United States of America, having a mailing address of Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/523,481**, filed **June 22, 2017**;

and have filed U.S. Provisional Patent Application Serial No.: **62/636,510**, filed **February 28, 2018**;

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, Novartis Institute for Functional Genomics, Inc. dba Genomics Institute of the Novartis Research Foundation (GNF), hereinafter referred to as the "ASSIGNEE", of 10675 John Jay Hopkins Drive, San Diego, CA 92121, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for

¹ I appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

June 20 2018
Date

John Delmas Venable III
John Delmas Venable III

Witnessed by:

Linda Faust
Name: Linda Faust
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Susan Slesnovich
Name: SUSAN SLESNOVICH
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation

Executed this 20 day of June, 20 18.

BY Julie McCarthy
Name: Julie McCarthy
Title: Authorized Signatory

Witnessed by:

J. Kalliomäki
Name: J. Kalliomäki
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Susan Semmel
Name: SUSAN SEMMEL
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

ASSIGNMENT

WHEREAS, We, **Bianka Prinz**, a citizen of Germany, having a mailing address of Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766; and **Jerry M. Thomas**, a citizen of the United States of America, having a mailing address of Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/523,481** filed **June 22, 2017**;

and filed U.S. Provisional Patent Application Serial No.: **62/636,510** filed **February 28, 2018**;

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, Adimab, LLC, hereinafter referred to as the "ASSIGNEE", of 7 Lucent Drive, Lebanon, NH 03766, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

3/28/18
Date

Bianka Prinz
Bianka Prinz


Witnessed by:

3/28/18
Name:
Address:

Paul White
Name: Paul White
Address: 7 Lucent Dr. Lebanon, NH 03755

Amy H Bray
Amy H Bray
7 Lucent Dr
Lebanon NH 03766

3/26/2018
Date


Jerry M. Thomas


Witnessed by:


Name: Vivian Thomas
Address: 12872 Francine Pl
Poway CA 92064


Name: Gordon Reels
Address: 8295 San Marcos Rd
Atascadero, CA 93422

Adimab, LLC


Executed this 28th day of March, 2018.

BY  L.S.

Name: ERIC KRAULAND
Title: Authorized Signatory

Witnessed by:


Name: Philip Chase
Address: 58 Rockester Rd.
Norton MA 02458


Name: Amy H. Bray
Address: 7 Lucent Dr
Lebanon NH 03266

ASSIGNMENT

This Assignment Agreement is entered into by and between **Novartis Institute for Functional Genomics, Inc. dba Genomics Institute of the Novartis Research Foundation (GNF)**, 10675 John Jay Hopkins Drive, San Diego, CA 92121, a company organized under the laws of Delaware, and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

WHEREAS, Novartis Institute for Functional Genomics, Inc., hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of John Venable, by virtue of the assignment dated 6/20/2018 for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **Novartis Institute for Functional Genomics, Inc.** does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **June 22, 2017** and accorded U.S. Provisional Patent Application No.: **62/523,481**;

and filed in the United States Patent and Trademark Office on **February 28, 2018** and accorded Application Number **62/636,510**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____;¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the

¹ Novartis Institute for Functional Genomics, Inc. appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by Novartis Institute for Functional Genomics, Inc. if this sale, assignment and transfer had not been made.

Novartis Institute for Functional Genomics, Inc. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Novartis Institute for Functional Genomics, Inc. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation

Executed this 20 day of June, 2018.

BY Julie McCarthy
Name: Julie McCarthy
Title: Authorized Signatory


Witnessed by:

J. Kallianay
Name: J.T. Kallianay
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Susan Semmes
Name: SUSAN SEMMES
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

NOVARTIS AG

Executed this 20th day of June, 2018.


BY 
Name: Emily T. Wu
Title: Authorized Signatory

Witnessed by:



Name: Jill Kalliamayi
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121



Name: SUSAN SEMMES
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

Executed this 20th day of June, 2018.

BY 
Name: Kun Wang
Title: Authorized Signatory

Witnessed by:


Name: Jill Kalliamayi
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121


Name: SUSAN SEMMES
Address: 10675 John Jay Hopkins Drive
San Diego, California 92121

ASSIGNMENT

WHEREAS, We, **Kulandayan Kasi Subramanian**, a citizen of India, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; and **Marie-Louise Fjaellskog**, a citizen of Sweden, having a mailing address of 48 School Street, Lexington, MA 02421; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/636,510** filed **February 28, 2018;**

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, Novartis Institutes for BioMedical Research, Inc., hereinafter referred to as the "ASSIGNEE", of 250 Massachusetts Avenue, Cambridge, MA 02139, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.


to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.


AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.


IN WITNESS WHEREOF, I have hereunto set my hand and seal.

6/18/08
Date


Kulandayan Kasi Subramanian

Witnessed by:


Name: Kathleen M. Drury
Address: 700 Main Street
Cambridge, MA 02139


Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

Date

Marie-Louise Fjaellskog


Witnessed by:

Name:
Address:


Name:
Address:


Novartis Institutes for BioMedical Research Inc.

Executed this 20 day of June, 2018.

BY  L.S.
Name: Stephanie Greis
Title: Authorized Signatory

Witnessed by:


Name:
Address:  **Tara M. Melanson**
700 Main Street
Cambridge, MA 02139


Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

WHEREAS, We, **Kulandayan Kasi Subramanian**, a citizen of India, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; and **Marie-Louise Fjaellskog**, a citizen of Sweden, having a mailing address of 48 School Street, Lexington, MA 02421; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/636,510** filed **February 28, 2018;**

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;

AND, WHEREAS, **Novartis Institutes for BioMedical Research, Inc.**, hereinafter referred to as the "ASSIGNEE", of 250 Massachusetts Avenue, Cambridge, MA 02139, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

Date

Kulandayan Kasi Subramanian

Witnessed by:

Name:
Address:

Name:
Address:


19 JUNE 2018

Date


Marie-Louise Fjaellskog


Witnessed by:


Name: Melissa Hackel.
Address: 784 Memorial Drive
Cambridge, MA 02139



Name: Peter Berry
Address: 784 Memorial Drive
Cambridge, MA 02139

Novartis Institutes for BioMedical Research Inc.

Executed this 20 day of June, 2018.

BY  L.S.
Name: Stephanie Greis
Title: Authorized Signatory

Witnessed by:


Name: Tara M. Melanson
Address: 700 Main Street
Cambridge, MA 02139


Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

WHEREAS, We, **Viviana Cremasco**, a citizen of the United States of America, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; **Glenn Dranoff**, a citizen of the United States of America, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; and **Catherine Anne Sabatos-Peyton**, a citizen of the United States of America, having a mailing address of Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/636,510** filed **February 28, 2018**;

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, Novartis Institutes for BioMedical Research, Inc., hereinafter referred to as the "ASSIGNEE", of 250 Massachusetts Avenue, Cambridge, MA 02139, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

05/31/18
Date

Viviana Cremasco
Viviana Cremasco

Witnessed by:

Kathleen M. Drury
Name:
Address: **Kathleen M. Drury**
700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: **Susan M. Dillon**
Address: **700 Main Street**
Cambridge, MA 02139 US

May 28, 2018
Date


Glenn Dranoff

Witnessed by:

Kendra Mar
Name: KENDRA MAR
Address: 250 Massachusetts Ave
Cambridge, MA 02139

Kathleen M. Drury
Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139

5/31/2018
Date

Catherine Anne Sabatos-Peyton
Catherine Anne Sabatos-Peyton

Witnessed by:

Kathleen M. Drury
Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

Novartis Institutes for BioMedical Research Inc.

Executed this 5 day of June, 2018.

BY Stephanie K. Oels L.S.

Name: Stephanie K. Oels
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name:
Address: **Kathleen M. Drury**
700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

WHEREAS, I, Ansgar Brock, a citizen of Germany, having a mailing address of c/o Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/636,510** filed **February 28, 2018;**

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, Novartis Institute for Functional Genomics, Inc. dba Genomics Institute of the Novartis Research Foundation (GNF), hereinafter referred to as the "ASSIGNEE", of 10675 John Jay Hopkins Drive, San Diego, CA 92121, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries,

¹ I appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

5-24-2018
Date

Ansgar Brock
Ansgar Brock

Witnessed by:

J. H. Kalliomaa
Name: J. H. Kalliomaa
Address: 10675 John Jay Hopkins Dr.
San Diego, CA 92121

Susan Semmich
Name: SUSAN SEMMICH
Address: 10675 JOHN JAY HOPKINS DRIVE
SAN DIEGO CA 92121

Novartis Institute for Functional Genomics, Inc., dba Genomics Institute of the Novartis
Research Foundation

Executed this 5th day of June, 2008.

BY Simone Corriveau
Name: SIMONE CORRIVEAU
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name:
Address: **Kathleen M. Drury**
700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

WHEREAS, We, **Scott Chapel**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Andrew Lake**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Alison Paterson**, a citizen of South Africa, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Rachel W. O'Connor**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; **Michael Warren**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; and **Pamela Holland**, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

for which we have filed U.S. Provisional Patent Application Serial No.: **62/636,510** filed **February 28, 2018;**

and/or filed in the United States Patent and Trademark Office on _____
and accorded Application Number _____;

and/or filed as a PCT International Application on _____ and
accorded International Patent Application Number _____;¹

AND, WHEREAS, **Surface Oncology, Inc.**, hereinafter referred to as the "ASSIGNEE", of 50 Hampshire Street, Cambridge, MA 02139, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have

¹ We appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

4/18/18
Date


Scott Chapel
Scott Chapel

Witnessed by:

Eileen M Woodbury
Name: Eileen M. Woodbury
Address: 66 Garden Lane
Apt 3
Waltham, MA 02452

Christine Eva Miller
Name: Christine Eva Miller
Address: 456 Main St
Amesbury, MA 01913

23 April 2018
Date


Andrew Lake

Witnessed by:

Eileen M Woodbury
Name: Eileen M. Woodbury
Address: 6 Garden Lane
Apt 3
Waltham, MA 02452

Christine Miller
Name: Christine Miller
Address: 456 Main St
Amesbury, MA
01913

4/23/2018
Date


Alison Paterson
Alison Paterson

Witnessed by:

Eileen H Woodbury
Name: Eileen H Woodbury
Address: 6 Garden Lane
Apt 3
Waltham, MA 02452

Christine Miller
Name: Christine Miller
Address: 456 Main St
Amesbury, MA
01913

4/12/2018
Date


Rachel W. O'Connor

Witnessed by:

<u>Eileen M Woodbury</u>	<u>Christine Miller</u>
Name: Eileen M. Woodbury	Name: Christine Miller
Address: 6 Garden Lane, Apt. 3	Address: 456 Main St
Waltham, MA 02452.	Amesbury MA 01913

4/18/2018
Date

Michael Warren
Michael Warren

Witnessed by:

Eileen M Woodbury
Name: Eileen M. Woodbury
Address: 6 Garden Lane
Apt. 3
Waltham, MA 02452

Christine Miller
Name: christine m. lter
Address: 456 Main St
Amesbury, MA
01913

April 23, 2018
Date

Pamela W
Pamela Holland

Witnessed by:

Eileen M Woodbury
Name: Eileen M. Woodbury
Address: 6 Garden Lane
Apt. B
Waltham, MA 02452

Christine Miller
Name: Christine Miller
Address: 456 Main St.
Amesbury, MA
01913

Surface Oncology, Inc.

Executed this 23rd day of April, 2018.

BY S. Fay L.S.
Name: Sandra Fay-Richard
Title: Authorized Signatory

Witnessed by:

<u>Eileen M. Woodbury</u>	<u>Christine Miller</u>
Name: <u>Eileen M. Woodbury</u>	Name: <u>Christine Miller</u>
Address: <u>6 Garden Lane</u>	Address: <u>456 Main St.</u>
<u>Apt. 3</u>	<u>Amesbury, MA</u>
<u>Waltham, Ma 02452</u>	<u>01913</u>

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Ave., Cambridge, MA 02139, USA, a company organized under the laws of Delaware, and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

WHEREAS, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of Kulandayan Kasi Subramanian, Marie-Louise Fjaellskog, by virtue of the assignments dated 6/18/2018 and 6/19/2018, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **February 28, 2018** and accorded U.S. Provisional Patent Application No.: **62/636,510**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____; and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____.¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and

¹ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(c);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. if this sale, assignment and transfer had not been made.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

Executed this 20 day of June, 2018.

BY [Signature] L.S.
Name: Stephanie Geis
Title: Authorized Signatory

Witnessed by:

[Signature]
Name: **Tara M. Melanson**
Address: **700 Main Street
Cambridge, MA 02139**

[Signature]
Name: **Susan M. Dillon**
Address: **700 Main Street
Cambridge, MA 02139 US**

NOVARTIS AG

Executed this 20th day of JUNE, 2013.

BY [Signature] L.S.
Name: Taddeo Kani
Title: Authorized Signatory

Witnessed by:

[Signature: Tara M. Melanson]
Name:
Address: **Tara M. Melanson
700 Main Street
Cambridge, MA 02139**

[Signature: Susan M. Dillon]
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

BY [Signature] L.S.
Name: Scott W. Coffin-Klein
Title: Authorized Signatory

Witnessed by:

[Signature: Tara M. Melanson]
Name:
Address: **Tara M. Melanson
700 Main Street
Cambridge, MA 02139**

[Signature: Susan M. Dillon]
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.**, 250 Massachusetts Ave., Cambridge, MA 02139, USA, a company organized under the laws of Delaware, and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

WHEREAS, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of Viviana Cremasco, Glenn Dranoff, and Catherine Anne Sabatos-Peyton, by virtue of the assignments dated 5/31/2018, 5/28/2018, and 5/31/2018, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.** does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **February 28, 2018** and accorded U.S. Provisional Patent Application No.: **62/636,510**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____; and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____;¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and

¹ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. if this sale, assignment and transfer had not been made.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.


Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.


This Assignment is effective as from the earliest priority date as stated above.


NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

Executed this 5 day of June, 2018.

BY  L.S.
Name: Stephanie K. Bejs
Title: Authorized Signatory

Witnessed by:


Name: Kathleen M. Drury
Address: 700 Main Street
Cambridge, MA 02139


Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

NOVARTIS AG

Executed this 5th day of June, 2018.

BY Safiyah Watson L.S.
Name: Safiyah Watson
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name: Kathleen M. Drury
Address: 700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

BY Judith Kuntz L.S.
Name: Judith Kuntz
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name: Kathleen M. Drury
Address: 700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between **Novartis Institute for Functional Genomics, Inc. dba Genomics Institute of the Novartis Research Foundation (GNF)**, 10675 John Jay Hopkins Drive, San Diego, CA 92121, a company organized under the laws of Delaware, and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

WHEREAS, **Novartis Institute for Functional Genomics, Inc.**, hereinafter generally referred to as "ASSIGNOR," has acquired the entire right, title and interest of Ansgar Brock, by virtue of the assignment dated 5/24/2008, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **Novartis Institute for Functional Genomics, Inc.** does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

filed in the United States Patent and Trademark Office on **February 28, 2018** and accorded U.S. Provisional Patent Application No.: **62/636,510**;

and/or filed in the United States Patent and Trademark Office on _____ and accorded Application Number _____; and/or filed as a PCT International Application on _____ and accorded International Patent Application Number _____;¹

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and

¹ Novartis Institute for Functional Genomics, Inc. appoints, authorizes and requests the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by Novartis Institute for Functional Genomics, Inc. if this sale, assignment and transfer had not been made.

Novartis Institute for Functional Genomics, Inc. hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

Novartis Institute for Functional Genomics, Inc. hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and

discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Novartis Institute for Functional Genomics, Inc.

Executed this 5th day of June, 2015.

BY Simone Coliveau L.S.
Name: Simone Coliveau
Title: Authorized Signatory

Witnessed by:

Kathleen M Drury
Name:
Address: **Kathleen M. Drury
700 Main Street
Cambridge, MA 02139**

Susan M Dillon
Name:
Address: **Susan M. Dillon
700 Main Street
Cambridge, MA 02139 US**

NOVARTIS AG

Executed this 5th day of June, 2018.

BY Safiyah Watson L.S.
Name: Safiyah Watson
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

BY Judith Kuntz L.S.
Name: Judith Kuntz
Title: Authorized Signatory

Witnessed by:

Kathleen M. Drury
Name:
Address: Kathleen M. Drury
700 Main Street
Cambridge, MA 02139

Susan M. Dillon
Name: Susan M. Dillon
Address: 700 Main Street
Cambridge, MA 02139 US

ASSIGNMENT

This Assignment Agreement is entered into by and between

**JONATHAN HILL, c/o SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139, a citizen of CANADA;**

**CHRISTINE MILLER, c/o SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139, a citizen of THE UNITED STATES OF AMERICA;**

(hereinafter "Inventor(s)"), and **SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139**, a company organized under the laws of THE STATE OF
DELAWARE.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, SURFACE ONCOLOGY, INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to SURFACE ONCOLOGY, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

and filed as International Application Number PCT/US2018/038775, filed on June 21, 2018;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates,


and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the law of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.


Executed this 12 day of December, 2019.



JONATHAN HILL




Witness Rebecca K Proctor
State Massachusetts



Witness Ben McIntyre
State Massachusetts


Executed this 11 day of December, 2019.



CHRISTINE MILLER



Witness Paige Baldwin
State Massachusetts




Witness Rebecca K Proctor
State Massachusetts

SURFACE ONCOLOGY, INC.


Executed this 11th day of December, 2019.

BY 

NAME: Chandran Adams
Authorized Signatory


Witness Ben Montenegro

State Massachusetts


Witness Rebecca K. Proctor

State Massachusetts

ASSIGNMENT

This Assignment Agreement is entered into by and between

**JONATHAN HILL, c/o SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139, a citizen of CANADA;**

**CHRISTINE MILLER, c/o SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139, a citizen of THE UNITED STATES OF AMERICA;**

(hereinafter "Inventor(s)"), and **SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139**, a company organized under the laws of THE STATE OF
DELAWARE.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, SURFACE ONCOLOGY, INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to SURFACE ONCOLOGY, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

and filed in the United States Patent and Trademark Office on June 22, 2017 and accorded Application Number 62/523,481;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable

law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates,


reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.


This Assignment shall be governed by the law of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.


Executed this 12 day of December, 2019.



JONATHAN HILL




Witness Rebecca K. Proctor
State Massachusetts




Witness Ben Montgomery
State Massachusetts


Executed this 11 day of December, 2019.



CHRISTINE MILLER



Witness Paige Baldwin
State Massachusetts



Witness Rebecca K. Proctor
State Massachusetts


SURFACE ONCOLOGY, INC.

Executed this 11th day of December, 2019.


BY


NAME: Chandra Adams
Authorized Signatory

Witness


Ben Montgomery
State Massachusetts

Witness


Rebecca K. Proctor
State Massachusetts

ASSIGNMENT

This Assignment Agreement is entered into by and between

**JONATHAN HILL, c/o SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139, a citizen of CANADA;**

**CHRISTINE MILLER, c/o SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139, a citizen of THE UNITED STATES OF AMERICA;**

(hereinafter "Inventor(s)"), and **SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET,
CAMBRIDGE, MA 02139**, a company organized under the laws of THE STATE OF
DELAWARE.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, SURFACE ONCOLOGY, INC. is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to SURFACE ONCOLOGY, INC. and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

ANTIBODY MOLECULES TO CD73 AND USES THEREOF

and filed in the United States Patent and Trademark Office on February 28, 2018 and accorded Application Number 62/636,510;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable

law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates,


reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.


This Assignment shall be governed by the law of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.


Executed this 11 day of December, 2019.



JONATHAN HILL




Witness Rebecca K Proctor
State Massachusetts




Witness Ben Montgomery
State Massachusetts


Executed this 11 day of December, 2019.



CHRISTINE MILLER



Witness Paige Baldwin
State Massachusetts



Witness Rebecca K Proctor
State Massachusetts

SURFACE ONCOLOGY, INC.

Executed this 11th day of December, 2019.

BY

NAME:

Authorized Signatory

Witness

State

Witness

State

ASSIGNMENT

WHEREAS, I, Michael Gladstone, a citizen of the United States of America, having a mailing address of Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139; hereinafter generally referred to as "ASSIGNOR," have invented a certain new and useful

ANTIBODY MOLECULES TO CD73 AND USES THEREOF;

which has been filed in the United States Patent and Trademark Office on **June 22, 2017** and accorded U.S. Provisional Patent Application Serial Number **62/523,481**;

and filed in the United States Patent and Trademark Office on **February 28, 2018** and accorded U.S. Provisional Patent Application Serial Number **62/636,510**;

and filed in the United States Patent and Trademark Office on **June 21, 2018** and accorded Application Number **16/014744**;

and filed as a PCT International Application on **June 21, 2018** and accorded International Patent Application Number **PCT/US2018/038775**;

and/or filed in _____ on _____ and
accorded Application Number _____.¹

AND, WHEREAS, **Surface Oncology, Inc.**, hereinafter referred to as the "ASSIGNEE", of 50 Hampshire Street, Cambridge, MA 02139, a company organized by the laws of Delaware, is desirous of acquiring the entire right, title and interest in and to the said inventions or improvements and in and to the said application, and to any patent application(s) corresponding thereto, and in, to and under any and all Letters Patent which may be granted on or as a result thereof in any and all countries:

NOW, THEREFORE, for and in exchange for valuable consideration from the receipt of which is hereby acknowledged and intending to be bound, I, the said assignor, have sold, assigned, transferred and set over, effective as of the execution date of this assignment and by these presents do hereby sell, assign, transfer and set over to said assignee, the entire right, title and interest in and to said inventions or improvements and said provisional application and any

¹ I appoint, authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting in the spaces provided above the filing date and serial number of said application when known.

and all corresponding patent application(s) and continuations, divisions and renewals of and substitutes for said corresponding patent application(s), and in, to and under any and all Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and assign to and authorize said assignee, to file in my name corresponding patent applications for Letters Patent in all countries, the same to be held and enjoyed by said assignee, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by me had this assignment, sale and transfer not been made.

AND I hereby covenant that I have full right to convey the entire interest herein assigned, and that I have not executed and will not execute any agreement in conflict herewith, and I further covenant and agree that I will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said inventions or improvements, said application and said Letters Patent to said assignee, its successors, assigns, nominees or legal representatives, and I agree to communicate to said assignee, or to its nominee all known facts respecting said inventions or improvements, said application and said Letters Patent, to testify in any legal proceedings, to sign all lawful papers, to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything possible to aid said assignee, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries.

AND I hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents of applications as aforesaid, to issue to said assignee, as assignee of the entire right, title and interest, any and all Letters Patent for said inventions or improvements, including any and all Letters Patent of the United States which may be issued and granted on or as a result of the application aforesaid, in accordance with the terms of this assignment.

This assignment is effective as from the date before the filing date of the Argentine application claiming priority rights from the patent/design applications herein assigned.


IN WITNESS WHEREOF, I have hereunto set my hand and seal.

2/20/19
Date


Michael Gladstone


Witnessed by:


Name: STEPHANIE F. KOH
Address: ATLAS VENTURE
400 TECH SQ, 10TH FL
CAMBRIDGE, MA 02139


Name: Dana O'Connell
Address: Atlas Venture
400 Tech Sq. 10th Floor
Cambridge, MA 02139


Surface Oncology, Inc.

Executed this 21 day of February, 2009.

BY  L.S.
Name: Sandra Fay-Richard
Title: Authorized Signatory

Witnessed by:


Name: Rebecca Proctor
Address: 50 Hampshire St.
Cambridge, MA 02139


Name: Michael Bottani
Address: 50 Hampshire St.
Cambridge, MA 02139